Advertisement
Advertisement
August 15, 2022
Boston Scientific Acquires Obsidio
August 15, 2022—Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed Gel Embolic Material (GEM) technology for embolization of blood vessels in the peripheral vasculature. Specific terms of the transaction have not been disclosed.
According to Boston Scientific, Obsidio’s FDA-cleared GEM technology is a semisolid material packaged in a ready-to-use form. The catheter-delivered GEM agent’s gel-like composition enables controlled placement within patient anatomy. When placed, GEM immediately conforms to the targeted vasculature to create a barrier.
Peter Pattison, President, Interventional Oncology and Embolization, Peripheral Interventions, Boston Scientific, commented in the company’s press release, “The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients.
“This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions.”
Advertisement
Advertisement
